1. Home
  2. JAGX vs ENVB Comparison

JAGX vs ENVB Comparison

Compare JAGX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • ENVB
  • Stock Information
  • Founded
  • JAGX 2013
  • ENVB 1994
  • Country
  • JAGX United States
  • ENVB United States
  • Employees
  • JAGX N/A
  • ENVB N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • ENVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • JAGX Health Care
  • ENVB Health Care
  • Exchange
  • JAGX Nasdaq
  • ENVB Nasdaq
  • Market Cap
  • JAGX 3.4M
  • ENVB 3.1M
  • IPO Year
  • JAGX N/A
  • ENVB N/A
  • Fundamental
  • Price
  • JAGX $2.30
  • ENVB $1.32
  • Analyst Decision
  • JAGX Strong Buy
  • ENVB Strong Buy
  • Analyst Count
  • JAGX 1
  • ENVB 1
  • Target Price
  • JAGX $60.00
  • ENVB $10.00
  • AVG Volume (30 Days)
  • JAGX 97.0K
  • ENVB 154.2K
  • Earning Date
  • JAGX 08-12-2025
  • ENVB 08-11-2025
  • Dividend Yield
  • JAGX N/A
  • ENVB N/A
  • EPS Growth
  • JAGX N/A
  • ENVB N/A
  • EPS
  • JAGX N/A
  • ENVB N/A
  • Revenue
  • JAGX $11,552,000.00
  • ENVB N/A
  • Revenue This Year
  • JAGX $22.41
  • ENVB N/A
  • Revenue Next Year
  • JAGX $30.00
  • ENVB N/A
  • P/E Ratio
  • JAGX N/A
  • ENVB N/A
  • Revenue Growth
  • JAGX 13.93
  • ENVB N/A
  • 52 Week Low
  • JAGX $2.27
  • ENVB $1.01
  • 52 Week High
  • JAGX $110.75
  • ENVB $11.55
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 28.65
  • ENVB 52.44
  • Support Level
  • JAGX $2.28
  • ENVB $1.18
  • Resistance Level
  • JAGX $2.79
  • ENVB $1.37
  • Average True Range (ATR)
  • JAGX 0.14
  • ENVB 0.06
  • MACD
  • JAGX 0.09
  • ENVB 0.01
  • Stochastic Oscillator
  • JAGX 3.92
  • ENVB 75.68

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: